Pharmacological strategies to improve cardiovascular health in CAH include optimized glucocorticoid replacement, adjunctive antiandrogen therapies, insulin sensitizers, statins, and renin–angiotensin system inhibitors, although disease-specific evidence remains limited. The gene discussed is INS; the disease is congenital adrenal hyperplasia.